Skip to main content

Table 1 A summary of Thimerosal-containing DTaP vaccine administration in comparison to Thimerosal-free DTaP vaccine as a risk factor for ASD adverse event reports in the VAERS

From: A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States

Group examined

Number autism/Autism spectrum disorder events

Net number of doses distributed (1998–2000)

Risk ratio (95% CI)

p-value

Thimerosal-Containing DTaP Vaccine

38

16,335,650

  
   

2.02 (1.15–3.56)

< 0.02

Thimerosal-Free DTaP Vaccine

17

14,794,210

 Â